These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 17566112

  • 1. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males.
    Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A.
    Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E604-9. PubMed ID: 17566112
    [Abstract] [Full Text] [Related]

  • 2. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects.
    Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A.
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1062-8. PubMed ID: 17148749
    [Abstract] [Full Text] [Related]

  • 3. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
    Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, Holst JJ, Astrup A, Sjödin A.
    Am J Physiol Endocrinol Metab; 2014 Jun 01; 306(11):E1248-56. PubMed ID: 24735885
    [Abstract] [Full Text] [Related]

  • 4. Effect of peptide YY3-36 on food intake in humans.
    Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C.
    Gastroenterology; 2005 Nov 01; 129(5):1430-6. PubMed ID: 16285944
    [Abstract] [Full Text] [Related]

  • 5. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
    Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR.
    Endocrinology; 2005 Dec 01; 146(12):5120-7. PubMed ID: 16150917
    [Abstract] [Full Text] [Related]

  • 6. Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite, and circulating levels of orexigenic/anorexigenic peptides.
    Rigamonti AE, Casnici C, Marelli O, De Col A, Tamini S, Lucchetti E, Tringali G, De Micheli R, Abbruzzese L, Bortolotti M, Cella SG, Sartorio A.
    Nutr Res; 2018 Apr 01; 52():71-79. PubMed ID: 29530622
    [Abstract] [Full Text] [Related]

  • 7. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man.
    Witte AB, Grybäck P, Holst JJ, Hilsted L, Hellström PM, Jacobsson H, Schmidt PT.
    Regul Pept; 2009 Nov 27; 158(1-3):57-62. PubMed ID: 19651163
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB.
    Diabetes Obes Metab; 2017 Sep 27; 19(9):1242-1251. PubMed ID: 28266779
    [Abstract] [Full Text] [Related]

  • 12. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
    Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR.
    Diabetes; 2010 Jul 27; 59(7):1635-9. PubMed ID: 20357366
    [Abstract] [Full Text] [Related]

  • 13. Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals varying in fat and carbohydrate and their association with hunger and the phases of satiety.
    Gibbons C, Caudwell P, Finlayson G, Webb DL, Hellström PM, Näslund E, Blundell JE.
    J Clin Endocrinol Metab; 2013 May 27; 98(5):E847-55. PubMed ID: 23509106
    [Abstract] [Full Text] [Related]

  • 14. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats.
    Nadkarni PP, Costanzo RM, Sakagami M.
    Diabetes Obes Metab; 2011 May 27; 13(5):408-17. PubMed ID: 21226821
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhaled PYY(3-36) dry-powder formulation for appetite suppression.
    Kuehl PJ, Boyden T, Dobry DE, Doyle-Eisele M, Friesen DT, McDonald JD, Murri BG, Vodak DT, Lyon DK.
    Drug Dev Ind Pharm; 2016 Jan 27; 42(1):150-156. PubMed ID: 26006332
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
    Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE, Schmitz F, Meier JJ.
    J Clin Endocrinol Metab; 2008 Oct 27; 93(10):3995-8. PubMed ID: 18647814
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.